Connect your AI

BridgeBio Pharma BBIO Lease Liability Payments - Remainder of Fiscal Year

Lease Liability Payments - Remainder of Fiscal Year at other companies

AbbottABT

$316M+9.0%

Royalty PharmaRPRX

——

Neurocrine BiosciencesNBIX

——

Krystal Biotech, Inc.KRYS

——

Medpace Holdings, Inc.MEDP

——

Other financials

Income statement

Revenue$194.5M+66.8%

Gross profit$184.6M+61.9%

Operating income-$106.0M-1.5%

Net income-$166.6M+1.8%

EPS (diluted)-$0.84+4.5%

Balance sheet

Cash & equivalents$882.0M+62.5%

Total debt$3.3B+32,101%

Total equity-$2.3B-38.2%

Total assets$1.4B+55.5%

Cash flow

Operating cash flow-$197.3M+1.0%

CapEx$69.0K—

Free cash flow-$197.3M+0.9%

Valuation

Market cap$12.98B+119%

Enterprise value$15.36B+178%

P/S22.4×-24.1×

Profitability

Gross margin95.1%-0.2pp

Operating margin-90.5%-41.2pp

Net margin-125.9%-54.5pp

FCF margin-76.8%—

Returns & leverage

Return on equity-216.8%—

Debt / equity2×—

Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's lease liability payments - remainder of fiscal year.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is BridgeBio Pharma's lease liability payments - remainder of fiscal year?: BridgeBio Pharma (BBIO) reported lease liability payments - remainder of fiscal year of $2.18M in Q1 2026.